{
    "doi": "https://doi.org/10.1182/blood.V118.21.5293.5293",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2059",
    "start_url_page_num": 2059,
    "is_scraped": "1",
    "article_title": "Right Ventricular Volumes and Function Normalized to Body Surface Area, Age and Sex in a Large Cohort of Well-Treated Thalassemia Major without Myocardial Iron Overload ",
    "article_date": "November 18, 2011",
    "session_type": "Thalassemia and Globin Gene Regulation",
    "topics": [
        "body surface area",
        "cooley's anemia",
        "heart ventricle",
        "iron overload",
        "myocardium",
        "cardiac mri",
        "anemia",
        "cardiomyopathy",
        "electrocardiogram",
        "fibrosis"
    ],
    "author_names": [
        "Antonella Meloni, PhD",
        "Giovanni Aquaro",
        "Lamia Ait-Ali",
        "Saveria Campisi",
        "Domenico Giuseppe D'Ascola",
        "Antonella Quarta, M.D.",
        "Pier Paolo Bitti",
        "Gaetano Roccamo, M.D.",
        "Maria Grazia Bisconte",
        "Basilia Piraino",
        "Maria Eliana Lai",
        "Angelo Peluso",
        "Stefania Renne",
        "Lucia De Franceschi, MD",
        "Vincenzo Positano",
        "Massimo Lombardi",
        "Alessia Pepe"
    ],
    "author_affiliations": [
        [
            "CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy, "
        ],
        [
            "CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy, "
        ],
        [
            "CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy, "
        ],
        [
            "U.O.S. Talassemia, A.O. Umberto I, Siracusa, Italy, "
        ],
        [
            "U.O. Microcitemie, A.O. \u201cBianchi-Melacrino-Morelli\u201d, Reggio Calabria, "
        ],
        [
            "Ematologia, Osp. \u201cA. Perrino\u201d, "
        ],
        [
            "Ambulatorio Trasfusionale Servizio Immunoematologia e Medicina Trasfusionale - Dipartimento dei Servizi, P. O. San Francesco. ASL Nuoro, Nuoro, Italy, "
        ],
        [
            "Unita\u0300 di Prevenzione e Cura delle Mictrocitemie, Ospedale \u201cCivile\u201d, S. Agata di Militello (ME), Italy, "
        ],
        [
            "Centro di Microcitemia, U. O. Ematologia, A. O. Cosenza - Presidio Osp. Annunziata, Cosenza, Italy, "
        ],
        [
            "Policlinico \u201cG. Martino\u201d, U.O. Genetica e Immunologia Pediatrica, Messina, Italy, "
        ],
        [
            "Internal Medicine, Adult Thalassemic Center, University of Cagliari, Cagliari, Italy, "
        ],
        [
            "Microcitemia, Azienda Unita\u0300 Sanitaria Locale TA/1 Presidio spedaliero CentraleO, taranto, Italy, "
        ],
        [
            "Struttura Complessa di Cardioradiologia-UTIC, P.O. \u201cGiovanni Paolo II\u201d, Lamezia Terme, "
        ],
        [
            "Clinical and Experimental Med., Policlinico GB Rossi, Univ. of Vero, Verona, Italy"
        ],
        [
            "CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy, "
        ],
        [
            "CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy, "
        ],
        [
            "CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy, "
        ]
    ],
    "first_author_latitude": "43.7067507",
    "first_author_longitude": "10.395378149999999",
    "abstract_text": "Abstract 5293 Introduction. Cardiovascular Magnetic Resonance (CMR) has provided the opportunity to quantify right ventricular (RV) parameters with excellent reproducibility and accuracy. The role of the RV is gaining ground in thalassemia major (TM) patients and this population could experience different \u201cnormal\u201d RV values due to chronic anemia and eventually pre-existing iron burdens. The aim of this study was to establish the ranges for normal RV volumes, mass and ejection fraction (EF) normalized to the influence of body surface area (BSA), age and sex from CMR in a large cohort of well-treated TM patients without myocardial iron overload. Methods. Among the 923 TM patients enrolled in the Myocardial Iron Overload (MIOT) network who underwent CMR for the assessment of cardiac iron overload, function and fibrosis, we selected 142 patients with no known risk factors or history of cardiac disease, normal electrocardiogram, no myocardial iron overload (all the cardiac segments with a normal T2* value) and no myocardial fibrosis. All patients had been regularly transfused and chelated since early childhood. Moreover, we studied 71 healthy subjects matched for age and sex. RV function parameters were quantitatively evaluated in a standard way by SSFP cine images using MASS\u00ae software. RV end-diastolic volume (EDV), end-systolic volume (ESV) and stroke volume (SV) were normalized by body surface area (EDVI, ESVI, SVI). Results. The table shows the comparison of the CMR parameters with differentiation for sex and age in TM patients and healthy subjects and the cut-off of normality defined as mean \u2013 2 standard deviation (SD). TM patients showed significantly lower BSA than the controls (P<0.0001). TM males (except age group 14\u201320 yrs) showed significantly higher RV EF compared to controls. In TM patients all LV volumes indexes were significantly larger in males than in females (P<0.0001 in all age groups). The EF was not different between the sexes. In males as well as in females the RV volumes were no significant different among the age groups, while in males the EF was significant different (P=0.004). Conclusion. In a large cohort of well-treated TM patients males showed significantly higher RV EF compared to controls. Due to the influence of BSA, sex and age, appropriate \u201cnormal\u201d reference ranges normalized to these variables should be used to avoid misdiagnosis of cardiomyopathy in the clinical arena in TM patients.  . < 14 . 14\u201320 . 20\u201330 . 30\u201340 . >=40 . . TM . H . P . TM . H . P . TM . H . P . TM . H . P . TM . H . P . Males  N=7  N=7   N=6  N=6   N=25  N=15   N=23  N=11   N=6  N=5   EDVI (ml/m2) 88\u00b116 (120) 80\u00b112 0.309 89\u00b116 (121) 89\u00b117 0.946 96\u00b121 (138) 103\u00b117 0.245 91\u00b116 (123) 82\u00b113 0.139 90\u00b113 (116) 81\u00b19 0.228 ESVI (ml/m2) 26\u00b13 (32) 31\u00b18 0.273 36\u00b17 (50) 35\u00b19 0.931 34\u00b18 (50) 44\u00b112 0.004  33\u00b18 (49) 33\u00b18 0.952 28\u00b16 (40) 35\u00b13 0.045  SVI (ml/m2) 61\u00b116 (93) 49\u00b16 0.108 53\u00b111 (75) 54\u00b110 0.836 61\u00b118 (97) 60\u00b19 0.882 58\u00b111 (80) 45\u00b117 0.010 62\u00b18 (78) 46\u00b18 0.007  EF (%) 68\u00b16 (56) 62\u00b15 0.048  59\u00b15 (49) 61\u00b15 0.579 64\u00b14 (56) 58\u00b16 0.001  64\u00b15 (54) 61\u00b17 0.189 69\u00b13 (63) 57\u00b15 <0.0001  Females  N=2  N=2   N=8  N=6   N=24  N=6   N=33  N=8   N=8  N=5   EDVI (ml/m2) 53\u00b116 (85) 61\u00b11 0.587 77\u00b18 (93) 79\u00b19 0.866 78\u00b114 (106) 78\u00b112 0.990 73\u00b113 (99) 77\u00b19 0.427 74\u00b111 (96) 70\u00b116 0.648 ESVI (ml/m2) 18\u00b11 (20) 20\u00b14 0.656 29\u00b15 (39) 30\u00b15 0.777 28\u00b18 (44) 31\u00b19 0.378 24\u00b17 (38) 26\u00b16 0.317 26\u00b15 (36) 25\u00b112 0.922 SVI (ml/m2) 35\u00b15 (45) 41\u00b13 0.635 47\u00b14 (55) 49\u00b17 0.673 51\u00b19 (69) 47\u00b17 0.384 49\u00b18 (65) 51\u00b110 0.738 47\u00b16 (59) 45\u00b15 0.517 EF (%) 64\u00b19 (46) 68\u00b16 0.687 62\u00b13 (56) 62\u00b16 0.997 65\u00b16 (53) 61\u00b17 0.171 68\u00b15 (58) 66\u00b18 0.329 67\u00b16 (55) 66\u00b18  . < 14 . 14\u201320 . 20\u201330 . 30\u201340 . >=40 . . TM . H . P . TM . H . P . TM . H . P . TM . H . P . TM . H . P . Males  N=7  N=7   N=6  N=6   N=25  N=15   N=23  N=11   N=6  N=5   EDVI (ml/m2) 88\u00b116 (120) 80\u00b112 0.309 89\u00b116 (121) 89\u00b117 0.946 96\u00b121 (138) 103\u00b117 0.245 91\u00b116 (123) 82\u00b113 0.139 90\u00b113 (116) 81\u00b19 0.228 ESVI (ml/m2) 26\u00b13 (32) 31\u00b18 0.273 36\u00b17 (50) 35\u00b19 0.931 34\u00b18 (50) 44\u00b112 0.004  33\u00b18 (49) 33\u00b18 0.952 28\u00b16 (40) 35\u00b13 0.045  SVI (ml/m2) 61\u00b116 (93) 49\u00b16 0.108 53\u00b111 (75) 54\u00b110 0.836 61\u00b118 (97) 60\u00b19 0.882 58\u00b111 (80) 45\u00b117 0.010 62\u00b18 (78) 46\u00b18 0.007  EF (%) 68\u00b16 (56) 62\u00b15 0.048  59\u00b15 (49) 61\u00b15 0.579 64\u00b14 (56) 58\u00b16 0.001  64\u00b15 (54) 61\u00b17 0.189 69\u00b13 (63) 57\u00b15 <0.0001  Females  N=2  N=2   N=8  N=6   N=24  N=6   N=33  N=8   N=8  N=5   EDVI (ml/m2) 53\u00b116 (85) 61\u00b11 0.587 77\u00b18 (93) 79\u00b19 0.866 78\u00b114 (106) 78\u00b112 0.990 73\u00b113 (99) 77\u00b19 0.427 74\u00b111 (96) 70\u00b116 0.648 ESVI (ml/m2) 18\u00b11 (20) 20\u00b14 0.656 29\u00b15 (39) 30\u00b15 0.777 28\u00b18 (44) 31\u00b19 0.378 24\u00b17 (38) 26\u00b16 0.317 26\u00b15 (36) 25\u00b112 0.922 SVI (ml/m2) 35\u00b15 (45) 41\u00b13 0.635 47\u00b14 (55) 49\u00b17 0.673 51\u00b19 (69) 47\u00b17 0.384 49\u00b18 (65) 51\u00b110 0.738 47\u00b16 (59) 45\u00b15 0.517 EF (%) 64\u00b19 (46) 68\u00b16 0.687 62\u00b13 (56) 62\u00b16 0.997 65\u00b16 (53) 61\u00b17 0.171 68\u00b15 (58) 66\u00b18 0.329 67\u00b16 (55) 66\u00b18  View Large Disclosures: No relevant conflicts of interest to declare."
}